Osi Pharmaceuticals Initiates Diabetes Drug Development Program
Posted on: Thursday, 4 September 2008, 12:00 CDT
Osi Pharmaceuticals has started a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the company is developing for the treatment of type 2 diabetes.
Discovered by Osi's diabetes and obesity research team, PSN821 demonstrated both effective glucose lowering and substantial reductions of body weight in pre-clinical studies. PSN821 is said to be the third development candidate discovered in-house that the company has moved into clinical development in 2008.
The double-blind, placebo-controlled, ascending single oral dose study is designed to provide preliminary information on the safety, tolerability and pharmacokinetics of PSN821 in healthy lean and overweight or obese subjects and patients with type 2 diabetes, as well as provide preliminary information on the effects of PSN821 on acute glucose control in the patient group.
Anker Lundemose, president of (OSI) Prosidion, said: "We are encouraged by the dual profile which has been observed for PSN821 and believe that it has the potential to be the first orally available therapy for type 2 diabetes that delivers both glucose control and substantial weight loss.
"PSN821 and our anti-obesity agent, PSN602, are part of an innovative strategy to discover and develop differentiated molecular targeted therapies for the treatment of type 2 diabetes and obesity."
Source: Datamonitor
Related Articles
- Genaera Reports Positive Data From Phase I Study of Diabetes and Obesity Drug
- DiObex to Present at Canaccord Adams Diabetes and Obesity Conference
- CytRx Awarded Federal Grant to Explore Novel Type 2 Diabetes and Obesity Treatment
- Dr. Luciano Rossetti, Internationally-Recognized Physician and Researcher, Joins Merck Research Laboratories in Key Leadership Role; Will Focus on Developing New Treatments for Diabetes and Obesity, Two Growing Global Health Problems
- OSI Summarizes Clinical Data on Tarceva(R) at the 2006 American Society of Clinical Oncology (ASCO) Meeting
- Risk Factors for Type 2 Diabetes in Women Attending Menopause Clinics in Italy: a Cross-Sectional Study
- Early-Onset Insulin-Resistant Diabetes in Obese Caucasians Has Features of Typical Type 2 Diabetes, but 3 Decades Earlier
- Determinants of Diabetes-Attributable Non-Blood Glucose-Lowering Medication Costs in Type 2 Diabetes: The Fremantle Diabetes Study
- Over Half of U.S. Diabetic Adults Obese
- China Owes Growing Number of Diabetics to Obesity
User Comments (0)
RSS Feeds